Cellectar reports 87.5% response rate in post-BTK inhibitor subgroup of Phase 2b Waldenström trial

Cellectar says iopofosine I 131 showed an 87.5% response rate in a 24-patient post-BTK inhibitor subgroup of its Phase 2b Waldenström macroglobulinemia trial.

Detected & updated continuously · Source: Nebula